Latigo Biotherapeutics Appoints Nima Farzan as Chief Executive Officer, Positioning Company for Rapid Growth
Farzan brings more than two decades’ leadership experience with a strong track record in fundraising and IPOs THOUSAND OAKS, Calif. – July 22, 2024 – Latigo Biotherapeutics Inc. (“Latigo”), a clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target…